Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology.

Literature DB >> 9524552

An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology.

C W Olanow¹, W C Koller.

Abstract

Entities: Disease

Mesh：

Substances：
Antiparkinson Agents

Year: 1998 PMID： 9524552 DOI： 10.1212/wnl.50.3_suppl_3.s1

Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910

Keyword Cloud
Cited

× No keyword cloud information.

31 in total

1. Treatment of early Parkinson's disease.

Authors: L Marsh; T M Dawson
Journal: BMJ Date: 2000-07-01

2. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa.

Authors: D A M C van de Vijver; R A C Roos; P A F Jansen; A J Porsius; A de Boer
Journal: Br J Clin Pharmacol Date: 2002-08 Impact factor: 4.335

Review 3. Imaging in cell-based therapy for neurodegenerative diseases.

Authors: Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal: Eur J Nucl Med Mol Imaging Date: 2005-12 Impact factor: 9.236

4. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Authors: Kimberly E Vanover; Adrienne J Betz; Suzanne M Weber; Francesco Bibbiani; Aiste Kielaite; David M Weiner; Robert E Davis; Thomas N Chase; John D Salamone
Journal: Pharmacol Biochem Behav Date: 2008-10 Impact factor: 3.533

An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology.

1. Treatment of early Parkinson's disease.

2. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa.

Review 3. Imaging in cell-based therapy for neurodegenerative diseases.

4. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Review 5. Neuropsychiatric aspects of Parkinson's disease: recent advances.

6. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan.

7. The putative neuroprotective role of dopamine agonists in Parkinson's disease.

Review 8. Early Parkinson's disease: what is the best approach to treatment.

9. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.

10. In vitro pharmacological profile of the A2A receptor antagonist istradefylline.